Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6P-AAV
- Development stage
- Preclinical
- Lead developer
- Ibex Biosciences
- Modality
- Gene Therapies
- Administration
- Intratumoral
01
Overview
6P-AAV is an investigational adeno-associated virus (AAV)-based gene therapy being developed by Ibex Biosciences for the treatment of glioblastoma. The therapy is specifically engineered to target glioma stem cells and tumor cells, which are key drivers of tumor progression, recurrence, and resistance to conventional therapies in glioblastoma multiforme. By utilizing an AAV vector, the treatment aims to deliver therapeutic genetic material directly to these malignant cell populations. While the specific transgene or molecular mechanism of action has not been publicly disclosed in detail, the program represents a targeted approach to treating aggressive brain tumors at the genetic level.
Beyond the preview
Go deeper on 6P-AAV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 6P-AAV.